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Abstract
Background: Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the western
world. Peroxisome proliferator-activated receptor γ (PPARγ) plays a key role in the regulation of the
energy balance, adipocyte differentiation and lipid biosynthesis. The aim was to investigate if the
polymorphism PPARγ2 Pro12Ala, which encodes a less efficient transcription factor, was associated with
risk of acute coronary disease and if there were interactions between this polymorphism and factors that
modify PPARγ activity, such as alcohol intake, smoking, and use of non-steroidal anti-inflammatory
medicine.
Methods: A case-cohort study including 1031 ACS cases and a sub-cohort of 1703 persons was nested
within the population-based prospective study Diet, Cancer and Health of 57,053 individuals.
Results: Homozygous male variant allele carriers of PPARγ2 Pro12Ala were at higher risk of ACS (HR =
2.12, 95% CI: 1.00–4.48) than homozygous carriers of the Pro-allele. Among men, there was a statistically
significant interaction between genotypes and alcohol intake such that homozygous variant allele carriers
with a low alcohol intake were at higher risk of ACS (HR = 25.3, CI: 16.5–38.7) compared to homozygous
common allele carriers (p for interaction < 0.0001). Overall, the association was only observed among
homozygous variant allele carriers. Thus, all the observed associations were obtained in subgroups
including small numbers of cases. It is therefore possible that the observed associations were due to
chance.
Conclusion: In the present study, there were no consistent associations between PPARγ Pro12Ala and
risk of ACS, and no consistent interaction with alcohol, BMI, NSAID or smoking in relation to ACS.
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Background
Acute coronary syndrome (ACS) is a major cause of mor-
bidity and mortality in the western world. Peroxisome
proliferator-activated receptor γ (PPARγ) plays a key role
in the regulation of the energy balance, adipocyte differ-
entiation and lipid biosynthesis [1]. PPARγ regulates the
expression of many adipose-specific genes via binding of
a heterodimer of PPARγ and RXR (Retinoid × receptor) to
regulatory response elements in target gene promoters [2].
The PPARγ Pro12Ala polymorphism results in a Pro to Ala
amino acid substitution at codon 12 which is only present
in the PPARγ2 isoform [2]. PPARγ2 is primarily expressed
in adipose tissue. The polymorphism is the only com-
monly occurring missense polymorphism in Caucasians
[2]. In vitro, the PPARγ2 Pro12Ala variant is a less active
transcription factor, resulting in lower transcription levels
of target genes [3-5]. There is evidence that the resulting
mutant transcription factor profoundly affects the energy
metabolism and energy balance linking the polymor-
phism to risk of diabetes mellitus [3,6]. Thus, in a meta
analysis variant Ala-allele carriers were at 20% lower risk
of diabetes mellitus [7]. Variant Ala-allele carriers have
also been reported to have higher insulin sensitivity [2].
Diabetes and overweight are risk factors for coronary heart
disease and ACS, and therefore the PPARγ2 Pro12Ala vari-
ant could be associated with lower risk of coronary heart
disease and ACS. Indeed, variant allele carriers of PPARγ2
Pro12Ala have been reported to be at lower risk of myocar-
dial infarction in some studies [8,9], but this was not con-
firmed in two prospective cohorts, where variant allele
carriers were at higher risk of coronary heart disease than
homozygous common allele carriers [10,11]. The varying
results may be explained by a low number of cases and
thus limited statistical power but may also be explained
by different distributions of potential effect modifiers in
the study populations. A number of lifestyle factors could
interact with PPAR-γ2 Pro12Ala in relation to risk of ACS
including alcohol intake, use of non-steroidal anti-
inflammatory drugs (NSAID), anthropometry and
tobacco smoking. Moreover, interaction has been
reported between the PPAR-γ2  Pro12Ala polymorphism
and alcohol intake in relation to plasma levels of lipopro-
teins [12].
We hypothesized that carriers of the PPAR-γ2  Pro12Ala
polymorphism would be at lower risk of ACS and that the
association was be modified by alcohol consumption,
smoking, NSAID use and body mass index (BMI). We
have tested the hypothesis in a case-cohort study includ-
ing 1031 cases with ACS and a random cohort sample of
1703 participants from the large prospective Diet, Cancer
and Health cohort, encompassing 57 053 Danes.
Methods
Subjects
The subjects were selected from the Danish Diet, Cancer
and Health study, an ongoing prospective cohort study
[13]. Between December 1993 and May 1997, 160,725
individuals aged 50 to 64 years, born in Denmark, living
in the Copenhagen and Aarhus areas were invited to par-
ticipate in the study. A total of 57 053 persons accepted
the invitation. At enrolment, detailed information on
diet, lifestyle, weight, height, reproduction status, medical
treatment, and other socio-economic characteristics and
environmental exposures were registered. The question-
naire is described in detail elsewhere [13]. Blood, urine,
and fat tissue was sampled and stored at -150°C.
A case-cohort study was designed using incident ACS,
which includes unstable angina pectoris, fatal and non-
fatal myocardial infarction as the outcome [14,15]. Infor-
mation on the disease endpoint was obtained by linkage
with central Danish registries via the unique identification
number assigned to all Danish citizens. Hospital records
of potential cases were retrieved for participants who were
registered with a first-time discharge diagnosis of ACS
(ICD-8 codes 410–410.99, 427.27 and ICD-10 codes
I20.0, I21.×, I46.×) in The Danish National Register of
Patients, which covers all hospital discharge diagnoses
since 1977 and all discharge diagnosis from out-patient
clinics since 1995 (until Jan 1, 2004). Cases were classi-
fied according to symptoms, signs, coronary biomarkers,
ECGs and/or autopsy findings in accordance with the cur-
rent recommendations of the American Heart Association
and the European Society of Cardiology (AHA/ECS) [14].
Further, linkage to the Cause of Death Register allowed for
identification of participants with ACS coded as a primary
or secondary cause of death (until Jan 1, 2004). In total,
1144 cases of ACS were identified and validated. The
cohort sample included 1816 participants selected as a
random sample of the entire cohort. This sample included
36 ASC cases. 183 samples were excluded because the last
cases were identified after the time of sample retrieval or
due to missing blood samples, and two participants were
excluded due to failed genotyping. Thirteen cases and 13
controls were excluded due to lack of information on
questionnaire data, leaving 1031 case subjects and 1703
participants in the sub-cohort including 34 cases who
were also sub-cohort members for the analysis.
Alcohol, NSAID, and other lifestyle variables
In the food-frequency questionnaire, alcohol intake was
recorded as the average frequency of intake of six types of
alcoholic beverage over the preceding year: the frequency
of consumption of three strengths of beer was recorded in
bottles (330 ml), wine in glasses (125 ml), fortified wine
in drinks (60 ml) and spirits in drinks (30 ml). The prede-BMC Medical Genetics 2009, 10:52 http://www.biomedcentral.com/1471-2350/10/52
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fined responses were in twelve categories, ranging from
"never" to "eight or more times a day". The alcohol con-
tent was calculated as follows: one bottle of light beer, 8.9
g ethanol; regular beer, 12.2 g ethanol; strong beer, 17.5 g
ethanol; one glass of wine, 12.2 g ethanol; one drink of
fortified wine, 9.3 g ethanol; and one drink of spirits, 9.9
g ethanol.
The lifestyle questionnaire included the following ques-
tion regarding use of NSAID: Have you taken more than
one pain relieving pill per month during the last year? If
the answer was yes, the participant was asked to record
how frequent they took each of the following types of
medications: "Aspirin", "Paracetamol", "Ibuprofen", or
"Other pain relievers". The latter category included NSAID
preparations other than aspirin and ibuprofen. Based on
all records, we classified study subjects according to their
use of "any NSAID" (≥ 2 pills per month during one year)
at baseline.
Data on hormone replacement therapy (HRT) was
obtained from the lifestyle questionnaire and the partici-
pants were classified according to use HRT (never, past or
current). Smoking status was recorded in three categories:
never smoker, current smoker and former smoker.
At the study clinics, anthropometric measurements,
including height and weight were obtained by profes-
sional staff members. BMI was calculated as weight (kg)
per height squared (m).
Blood sampling and storage
From each non-fasting participant a total of 30 ml blood
was collected in citrated (2 × 10 ml) and plain (1 × 10 ml)
Venojects. Plasma, serum, lymphocytes, and erythrocytes
were isolated and frozen at -20°C within 2 hours. At the
end of the day of collection, all samples were stored in liq-
uid nitrogen at -150°C.
Genotyping
DNA was isolated from frozen lymphocytes as described
by Miller et al [16]. Generally, 100 μg DNA were obtained
from 107 lymphocytes. PPAR2γ Pro12Ala (rs1801282) was
genotyped as previously described [17]. Laboratory staff
was blinded to the case/subcohort status of the subjects.
Twenty ng of DNA were used for genotyping in 5 μl con-
taining 1× Mastermix (Applied Biosystems, Nærum, Den-
mark), 100 nM probes, and 900 nM primers. Controls
were included in each run, and repeated genotyping of a
random 10% subset yielded 100% identical genotypes.
Measurement of blood lipids
Total Cholesterol and other blood lipids were measured
on an Advia 1650 from Bayer Diagnostics, NY, USA. For
total cholesterol kits ref. 01482198 were used. The inters-
eriel variation was 1.1%. For triglyceride kits ref.
09580156 was used with an interserial variation of 4.5%.
For HDL-cholesterol kits ref. 08058065 with an interseriel
variation of 2.0%. LDL-cholesterol was calculated by
Friedewald's formula.
Statistical methods
We used a case-cohort design with a sub-cohort of 1703
subjects drawn randomly, stratified on gender from the
whole cohort with 57,053 subjects. A Cox proportional
hazards model was used for analyses, as if the full cohort
were included, modified by a weighting scheme described
[18] and using a robust variance estimate. In the case-
cohort design, weights are assigned to each subject, one
for cases and N/n for non-cases in the sub-cohort, where
N (n) is the number of non-cases in the cohort (sub-
cohort). For women, N/n = 29,289/797 and for men, N/n
= 26,012/906.
Age was used as the time scale in the Cox regression
model. All models were sex specific and adjusted for base-
line values of established risk factors for ACS including
status of BMI, HRT, smoking status, NSAID use and alco-
hol intake.
We investigated possible interactions between polymor-
phism and alcohol intake, NSAID use, smoking status and
BMI using the likelihood ratio test. Analyses were done
using Stata version 9.2 (Stata Corporation, College Sta-
tion, Texas, US).
Approval
Diet, Cancer and Health and the present sub-study were
approved by the regional Ethics Committees on Human
Studies in Copenhagen and Aarhus (File nos.(KF)11-037/
01 and HKF-01-345/93), and by the Danish Data Protec-
tion Agency.
Results
The final case group consisted of 786 men and 245
women who were diagnosed with acute coronary syn-
drome after recruitment into the Diet, Cancer and Health
cohort and the final random cohort sample 906 men and
797 women selected from the cohort for whom genotypes
and information on lifestyle variables were available.
Cases and the cohort sample are described in Table 1.
Both male and female cases had a higher BMI, were more
likely to have diabetes mellitus, hypercholesterolemia,
and hypertension, be smokers and have a lower alcohol
intake than the cohort sample. They also had higher trig-
lyceride levels and lower HDL levels in plasma.
The genotype distribution of PPARγ  Pro12Ala was in
Hardy-Weinberg equilibrium for both men and women in
the cohort sample (results not shown). The allele fre-BMC Medical Genetics 2009, 10:52 http://www.biomedcentral.com/1471-2350/10/52
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Table 1: Baseline characteristics of the study participants.
Women Men
Variablea Cases
(n = 245)
Cohort sample
(n = 797)
Cases
(n = 786)
Cohort sample
(n = 906)
Age at entry (yrs) 60 (52–65) 56 (51–64) 58 (51–65) 56 (51–64)
BMI (kg/m2) 26.4 (20.1–35.2) 24.6 (19.7–33.7) 26.9 (22.4–34.1) 26.3 (21.6–32.4)
Waist (cm) 86 (69–107) 80 (67–105) 97 (83–117) 95 (82–113)
Diabetesb
Yes 5.3% 1.0% 5.4% 2.3%
No 90.2% 94.3% 88.5% 91.7%
Unknown 4.5% 4.7% 6.1% 6.0%
Hypercholesterolemiab
Yes 16.9% 6.1% 12.1% 9.7%
No 44.0% 48.4% 45.4% 52.0%
Unknown 39.1% 45.5% 42.5% 38.3%
Hypertension
Yes 40.0% 15.5% 22.2% 13.1%
No 51.8% 74.9% 61.0% 72.4%
Unknown 8.2% 9.6% 16.8% 14.5%
Postmenopausal
Yes 70.2% 57.8% N/A N/A
No 5.3% 17.5%
Unknown 24.5% 24.7%
HRT use
Current 26.5% 31.7% N/A N/A
Former 22.5% 15.7%
Never 51.0% 52.6%
Smoking
Current 59.2% 36.8% 59.3% 37.3%
Former 16.3% 21.4% 26.5% 35.4%
Never 24.5% 41.8% 14.2% 27.3%
Alcohol (g/d) 6 (0–38) 9 (0–40) 17 (1–72) 20 (1–83)
Plasma lipids (mmol/L)
Triglycerides 1.8 (0.9–4.7) 1.3 (0.7–3.2) 2.1 (0.9–5.3) 1.7 (0.8–4.4)
Cholesterol 6.5 (4.8–8.6) 6.0 (4.5–7.9) 6.3 (4.6–8.1) 5.9 (4.6–7.7)
HDL-C 1.6 (1.1–2.2) 1.8 (1.2–2.6) 1.3 (1.0–1.9) 1.4 (1.0–2.1)
a) Medians (5th and 95th percentiles) of continuous covariates. All lipids were obtained from non-fasting participants (n = 2610) b) Diagnosed with 
hypercholesterolemia.BMC Medical Genetics 2009, 10:52 http://www.biomedcentral.com/1471-2350/10/52
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Table 2: Association between PPARγ Pro12Ala and risk of acute coronary syndrome among men and women in the Diet, Cancer and 
Health Cohort
PPARγ Pro12Ala Ncase/Nnon-cases HRa
(95% CI)
pH R b
(95% CI)
pH R c
(95% CI)
p
Men
Pro/Pro 589/664 1.0 1.0
Pro/Ala 176/204 0.92
(0.73–1.17)
0.51 0.92
(0.72–1.18)
0.50 Not relevant
Ala/Ala 21/12 1.99
(0.98–4.05)
0.06 2.12
(1.00–4.48)
0.05 Not relevant
Pro/Ala & Ala/Ala 197/216 0.98
(0.78–1.23)
0.86 0.98
(0.77–1.24)
0.86 Not relevant
Women
Pro/Pro 181/581 1.0 1.0 1.0
Pro/Ala 62/193 0.96
(0.67–1.36)
0.80 0.93
(0.65–1.35)
0.75 0.96
(0.67–1.40)
0.85
Ala/Ala 2/15 0.38
(0.08–1.72)
0.21 0.37
(0.08–1.72)
0.21 0.40
(0.08–1.85)
0.24
Pro/Ala & Ala/Ala 64/208 0.91
(0.65–1.29)
0.60 0.89
(0.62–1.27)
0.53 0.92
(0.64–1.33)
0.60
a) Crude (only adjusted for age)
b) Adjusted for alcohol, smoking and NSAID
c) Adjusted for alcohol, smoking, NSAID, hormone replacement therapy and menopause status
Table 3: HR for acute coronary syndrome subdivided by alcohol intake and PPARγ Pro12Ala genotype.
Ncases/Nnon-cases HR (95% CI)
Alcohol intake g/day Alcohol intake g/day
PPARγ Pro12Ala < 4.0 4.0 < × < 12.0 > 12.0 < 4.0 4.0 < × < 12.0 > 12.0
Men
Pro/Pro 98/81 127/128 364/455 1a 0.86 (0.59–1.28) 0.70 (0.50–0.98)
Pro/Ala 30/19 41/37 105/148 1.41 (0.73–2.70) 0.90 (0.64–1.55) 0.58 (0.39–0.86)
Ala/Ala 4/0 4/1 13/11 40.7 (27.5–60.2) 2.30 (0.29–18.5) 1.09 (0.46–2.57)
P for interaction p < 0.0001
Pro/Pro 98/81 127/128 364/455 1b 0.91 (0.60–1.37) 0.69 (0.49–0.99)
Pro/Ala 30/19 41/37 105/148 1.30 (0.67–2.55) 0.78 (0.44–1.39) 0.60 (0.39–0.90)
Ala/Ala 4/0 4/1 13/11 25.3 (16.5–38.7) 3.18 (0.41–24.8) 1.11 (0.45–2.76)
P for interaction p < 0.0001
Women
Pro/Pro 76/157 50/205 55/219 1a 0.52 (0.34–0.80) 0.52 (0.34–0.79)
Pro/Ala 25/60 21/63 16/70 0.72 (0.41–1.27) 0.70 (0.39–1.27) 0.45 (0.23–0.88)
Ala/Ala 1/7 0/4 1/4 0.25 (0.29–2.15) No estimate 0.70 (0.08–6.50)
P for interaction 0.34
Pro/Pro 76/157 50/205 55/219 1b 0.53 (0.34–0.83) 0.51 (0.33–0.80)
Pro/Ala 25/60 21/63 16/70 0.73 (0.40–1.31) 0.71 (0.38–1.31) 0.44 (0.22–0.88)
Ala/Ala 1/7 0/4 1/4 0.27 (0.03–2.15) No estimate 0.52 (0.05–5.30)
P for interaction 0.46
Pro/Pro 76/157 50/205 55/219 1c 0.53 (0.34–0.84) 0.52 (0.33–0.82)
Pro/Ala 25/60 21/63 16/70 0.75 (0.41–1.35) 0.72 (0.38–1.35) 0.48 (0.24–0.86)
Ala/Ala 1/7 0/4 1/4 0.29 (0.03–2.59) No estimate 0.55 (0.05–5.71)
P for interaction 0.51
a) Crude analysis (age adjusted), b) Adjusted for smoking and alcohol intake, c) Adjusted for smoking, alcohol, menopause status and HRT useBMC Medical Genetics 2009, 10:52 http://www.biomedcentral.com/1471-2350/10/52
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quency of the variant allele was 0.130 among men and
0.141 among women in the random sample. This is simi-
lar to the 0.14 found previously for another sample of the
DHC cohort of 317 men and women matched on age and
sex to 317 basal cell carcinoma cases [19].
Among men, homozygous carriers of the variant allele of
PPARγ Pro12Ala were at higher risk of acute coronary syn-
drome than homozygous common allele carriers (hazard
ratio (HR) = 2.12, 95% confidence interval (CI): 1.00–
4.48) (Table 2). In an additive model, the polymorphism
was not statistically significantly associated with risk of
ACS (p = 0.70). A negative though statistically insignifi-
cant association was observed among women. The HR for
female homozygous carriers of the variant allele of PPARγ
Pro12Ala was 0.40 (0.08–1.85). In an additive model, the
polymorphism was not statistically significantly associ-
ated with risk of ACS (p = 0.35).
To investigate a possible interaction between PPARγ
Pro12Ala and alcohol intake, alcohol intake was subdi-
vided into tertiles according to the distribution of intake
among women in the cohort sample. 4 g/day and 12 g/
day were used as cut points among both men and women
(Table 3). For men, there was interaction between PPARγ
Pro12Ala and alcohol intake. The effect was primarily car-
ried by a high risk of ACS among homozygous variant
allele carriers who drank less than 4 gram alcohol/day
(HR = 25.3, CI: 16.5–38.7), which was not present among
those with a higher alcohol consumption. There was no
interaction between PPARγ  Pro12Ala and alcohol con-
sumption among women.
There was no interaction between PPARγ Pro12Ala and
BMI neither among men nor women (results not shown).
There was no interaction between PPARγ Pro12Ala and
NSAID use in relation to ACS, neither when aspirin use
was included in the group of 'no NSAID use' (table 4) nor
when aspirin use was included as a separate category
(results not shown).
Male smokers were at almost 3-fold higher risk of ASC
than non-smokers (additional file 1). There was no inter-
action between PPARγ  Pro12Ala and smoking for men.
Among women, there was interaction between PPARγ
Pro12Ala and smoking status (p = 0.001). Variant allele
carriers were at lower risk of ASC among never smokers
and past smokers. There was no association between cho-
lesterol levels and PPARγ  Pro12Ala, and no interaction
between PPARγ Pro12Ala and alcohol intake in relation to
cholesterol levels or triglyceride levels (additional file 2).
Discussion
In this rather large, prospective study of the association
between PPARγ Pro12Ala and risk of ACS, there was very
little effect of the PPARγ  Pro12Ala polymorphism.
Homozygous variant allele carriers were at higher risk
among men whereas the variant allele was associated with
lower risk among women. The associations were only
observed among homozygous carriers of the variant
allele. Potential effect modification from intake of alco-
hol, use of NSAID, anthropometric variables and tobacco
smoking was explored, but no consistent interactions
were observed. All significant associations were observed
Table 4: Risk of acute coronary syndrome in relation to use of NSAID. Aspirin users are included in 'No NSAID'
PPARγ Pro12Ala Ncases/Nnon-cases HRa 95% CI HRb 95% CI
Men NSAID NSAID NSAID
NO YES NO YES NO YES
Pro/Pro 531/622 58/42 1.00 - 1.63 1.07–2.47 1.00 - 1.58 1.00–2.48
Pro/Ala 156/190 20/14 0.91 0.75–1.17 1.61 0.79–3.25 0.91 0.70–1.17 1.63 0.79–3.37
Ala/Ala 20/11 1/1 2.07 0.99–4.32 2.00 0.13–30.5 2.36 1.09–5.13 1.10 0.07–17.7
P for interaction 0.918 0.670
Pro/Pro 531/622 58/42 1.00 - 1.63 1.07–2.47 1.00 - 1.58 1.00–2.48
Pro/Ala & Ala/Ala 176/201 21/15 0.96 0.77–1.24 1.62 0.72–3.23 0.97 0.76–1.25 1.60 0.79–3.23
P for interaction 0.958 0.929
Women
Pro/Pro 145/505 36/76 1.00 - 1.52 0.96–2.41 1.00 - 1.37 0.84–2.23
Pro/Ala 52/168 10/25 0.99 0.67–1.45 1.31 0.59–2.87 0.93 0.62–1.38 1.33 0.59–3.00
Ala/Ala 2/9 0/6 0.61 0.12–2.97 - - 0.54 0.11–2.71 - -
P for interaction 0.771 0.924
Pro/Pro 145/505 36/76 1.00 - 1.42 0.96–2.41 1.00 - 1.36 0.84–2.23
Pro/Ala & Ala/Ala 54/177 10/31 0.96 0.66–1.41 1.08 0.50–2.32 0.90 0.61–1.34 1.14 0.52–2.51
P for interaction 0.517 0.875
a) crude
b) adjusted for smoking status and alcohol consumptionBMC Medical Genetics 2009, 10:52 http://www.biomedcentral.com/1471-2350/10/52
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in subgroups with small numbers of cases and limited
power, indicating that the findings may be due to chance.
The results are in agreement with a recent meta-analysis
finding no association [20].
Our cases and controls were selected from the same
cohort, which together with an almost complete follow-
up of the participants minimized the risk for selection
bias. For all participants, information on lifestyle factors
was collected at enrolment, which minimized the risk for
differential misclassification between the cases and con-
trols. Furthermore, the use of only ACS cases confirmed
through medical records ensured a high validity of our
endpoint data.
We calculated separate risk estimates for men and women.
This is partly because the risk of acute coronary heart dis-
ease is very different between the sexes, partly because
some of the previous investigations were made among
men only [9]. Also the prevalence of potential effect mod-
ifiers varied between the sexes in the present cohort. It has
previously been reported that PPARγ  Pro12Ala interact
with the closely linked polymorphism PPARγ C14314T
[8,21,22]. In the present cohort of Danes, the two poly-
morphisms are closely linked, with 84% of the genotypes
being concordant and only 16% discordant [23]. We
therefore made no attempt to differentiate between the
effects of the two polymorphisms.
Among men, there was a statistically significant interac-
tion between PPARγ Pro12Ala and alcohol intake. Among
those who drank alcohol, variant allele carriers were at
higher risk of ACS at all levels of alcohol intake but the
association was strongest among participants with the
lowest alcohol intake where heterozygous carriers were at
1.3-fold higher risk (95%CI: 0.67–2.55) of ACS than
homozygous common allele carriers and homozygous
variant allele carriers at 25.3 (95%CI: 16.5–38.7) times
higher risk of ACS. These results are consistent with
another prospective study [10], where male carriers of the
variant allele were at 1.44-fold (95%CI: 1.00–2.07) higher
risk than homozygous common allele carriers in a cohort
where the average alcohol consumption among men was
7.0 g/day among controls and 5.9 g/day among cases.
Information on alcohol consumption was not included in
other studies [9,24]. However, the present findings
among those with a low alcohol intake rely on few cases,
and among women no consistent effect modification was
observed.
We were unable to reproduce a previously found interac-
tion between PPARγ Pro12Ala and overweight in relation
to coronary heart disease, where it was found that the var-
iant allele was a stronger risk factor among overweight
men and women [10]. We observed no interaction
between PPARγ Pro12Ala and blood levels of cholesterol,
or triglycerides, and no interaction with alcohol. Thus, we
were also unable to reproduce a previously found interac-
tion [12]. We have almost used the same cut-off value (4
g/day compared to 5 g/day), but the other study [12]
included much younger individuals with lower choles-
terol and triglyceride blood levels. Furthermore, the previ-
ous study did not subdivide by sex, although cholesterol
levels differ by sex. Studies of mice, which were specifi-
cally deleted for the PPARγ2 isoform of PPARγ had the
same bodyweight as common allele littermates when fed
chow, but developed less adipose tissue when put on a
high fat diet [25]. Thus, it is possible that the lack of asso-
ciations for the PPARγ Pro12Ala is because of the relatively
low fat diets among the present cohort members.
A number of commonly used NSAIDs activate PPARγ
[26], and thus, if differences in PPARγ activity is related to
risk of ACS, then interaction with NSAID use would be
expected. We have previously observed interaction
between PPARγ Pro12Ala and NSAID use in relation to risk
of both breast cancer and lung cancer [17,27] using the
Diet, Cancer and Health cohort and the same definitions
of NSAIDs as used here. No interaction between PPARγ
Pro12Ala and NSAID use in relation to risk of ACS was,
however, observed in this study. This indicates either that
PPARγ activity is not related to risk of ACS, or that the acti-
vation of target genes in relation to risk of ACS is different
than for cancer.
Among women, there was interaction between smoking
status and PPARγ Pro12Ala. Variant allele carriers were at
lower risk of ACS than homozygous common allele carri-
ers among never and past smokers. We have previously
observed the same pattern in relation to lung cancer,
although there was no statistically significant interaction
[27]. Among men, there seemed to be only additive effects
of  PPARγ  Pro12Ala and smoking. Since the interaction
among women relied on relatively few persons among
non-smokers and variant allele carriers, the interaction
observed may be a chance finding.
Conclusion
In conclusion, there were no convincing associations
between PPARγ Pro12Ala and risk of ACS, and no system-
atic interaction with alcohol, BMI, NSAID or smoking in
relation to ACS.
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